Last reviewed · How we verify
Recombinant Interferon Alfa 2a
At a glance
| Generic name | Recombinant Interferon Alfa 2a |
|---|---|
| Also known as | Roferon-A |
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (PHASE3)
- High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma (PHASE3)
- Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients (PHASE1, PHASE2)
- Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (PHASE3)
- A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C (PHASE1, PHASE2)
- Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment (PHASE1)
- Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection (PHASE2)
- A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant Interferon Alfa 2a CI brief — competitive landscape report
- Recombinant Interferon Alfa 2a updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI